ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Characterization of Resistant Cytomegalovirus in Lung Transplant Recipients in the Modern Era.

S. Hammad, L. Shah, M. Restivo, H. Robbins, J. Scheffert.

NewYork-Presbyterian Hospital, New York, NY.

Meeting: 2016 American Transplant Congress

Abstract number: B279

Keywords: Cytomeglovirus, Infection, Lung transplantation, Viral therapy

Session Information

Date: Sunday, June 12, 2016

Session Name: Poster Session B: Lung Transplantation Posters

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Safety and Outcome of Ganciclovir-Resistant CMV Treated With Foscarnet: A Single Center Retrospective Study
  • Characteristics and Outcomes of Resistant Cytomegalovirus (CMV) Disease in Solid Organ Transplant (SOT) Patients

Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in lung transplant recipients (LTR) and the emergence of resistant CMV (rCMV) has increased. The purpose of this study is to characterize rCMV in LTR.

This is an IRB-approved, single-center retrospective study of LTR transplanted between 1/2010-12/2014 who developed rCMV. Patients receiving multi-organ transplants and re-transplants were excluded.

299 patients received a lung transplant during the study period. 16 (5%) developed rCMV. Baseline characteristics and outcomes are below.

All patients with rCMV were D+/R- and 94% received ganciclovir prophylaxis. 75% were transplanted in 2011-2013 and 82% developed rCMV in 2012-2014. Median time to develop rCMV was 378 days (IQR 227, 628). 50% were on CMV prophylaxis at the time of the first positive CMV PCR. Mortality was 25% and no trend was observed in the FEV1 change 6 months prior to and 6 months after rCMV. 38% had a change in CMV genotype, but all had resistance to ganciclovir at UL97. 94% were treated with combination antiviral therapy and foscarnet was most commonly used.

rCMV genes, n (%)  
Ganciclovir UL97

16 (100)

Ganciclovir UL54

4 (25)

Cidofovir UL54

5 (31)

Foscarnet UL54 4(25)
   
Antiviral agents used, n (%)  
Foscarnet 14 (88)
Ganciclovir 10 (63)
Valganciclovir 8 (50)
Cytomegalovirus immune globulin 3 (19)
Cidofovir 2 (14)
Leflunomide 2 (14)
Maribavir 2 (14)

There is an apparent increase in the incidence of rCMV over time. All patients were at high risk (D+/R-) for developing CMV and most required combination therapy with toxic antivirals. There was no trend in the change of FEV1 before and after rCMV. Additional study is warranted to confirm these findings and identify causes to further characterize the impact of rCMV on LTR.

CITATION INFORMATION: Hammad S, Shah L, Restivo M, Robbins H, Scheffert J. Characterization of Resistant Cytomegalovirus in Lung Transplant Recipients in the Modern Era. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Hammad S, Shah L, Restivo M, Robbins H, Scheffert J. Characterization of Resistant Cytomegalovirus in Lung Transplant Recipients in the Modern Era. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/characterization-of-resistant-cytomegalovirus-in-lung-transplant-recipients-in-the-modern-era/. Accessed February 28, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.